# Epidemiology and Management of Hypertension in the Hispanic Population A Review of the Available Literature

CorpusID: 12366298
 
tags: #Medicine

URL: [https://www.semanticscholar.org/paper/66a5c93b707cb25addc6a69af4947adc08a54945](https://www.semanticscholar.org/paper/66a5c93b707cb25addc6a69af4947adc08a54945)
 
| Is Survey?        | Result          |
| ----------------- | --------------- |
| By Classifier     | False |
| By Annotator      | (Not Annotated) |

---

Epidemiology and Management of Hypertension in the Hispanic Population A Review of the Available Literature


Nicolas J Guzman 
Medical Faculty Associates
Division of Renal Diseases and Hypertension
The George Washington University
WashingtonDCUSA

Epidemiology and Management of Hypertension in the Hispanic Population A Review of the Available Literature



## Introduction

Hispanic Americans (i.e. individuals of Mexican, Cuban, Puerto Rican, Dominican, South American, or Central American descent, or descendants of other Spanish cultures or races) are the youngest and fastest growing ethnic minority in the USA. In 2006, Hispanics made up 15% of the US population, and this number is expected to grow to 24% by 2050. [1] Studies have shown that Hispanic Americans have an increased cardiovascular risk compared with non-Hispanic Whites. [2,3] Therefore, it is important for US healthcare providers to be aware of cardiovascular health characteristics that may be unique to this subset of the population. As this segment of the population continues to grow, the financial burden of managing cardiovascular disease will increase as well. Cardiovascular disease accounts for the single largest proportion of both direct and indirect US healthcare costs annually, with costs estimated at roughly $300 billion in 2008 and rising rapidly. [4] By 2030, these costs are projected to exceed $800 billion annually. [4] Hypertension is the most common risk factor for cardiovascular disease, surpassing smoking, obesity, and diabetes mellitus, and is a significant predictor of premature death and cardiovascular disability. [4] According to 2008 estimates, 18% of Hispanic adults ‡18 years of age have been diagnosed with hypertension compared with 27% of non-Hispanic Whites and 32% of non-Hispanic Blacks. [5] However, in middle-aged and older adults (45-84 years), the crude incidence rate of hypertension per 1000 person-years was higher in Hispanics compared with non-Hispanic Whites (65.7 vs 56.8). [6] Moreover, compared with non-Hispanics, Hispanics are less likely to be aware of their hypertension, and are less likely to have their blood pressure (BP) adequately controlled. [2,7] Consequently, hypertension-related mortality rates have been increasing faster for certain Hispanic subgroups than for other ethnic groups. For example, between 1995 and 2002, hypertension-related mortality rates increased by 31% among Mexican Americans and by 46% among other Hispanic Americans (excluding Puerto Ricans and Cubans) compared with 27% among non-Hispanic Whites. [8] Unless steps are taken to increase the awareness of hypertension among Hispanics, this trend of increasing hypertension-related mortality is likely to continue. This appears to be the case particularly in younger individuals. Bersamin and colleagues, [9] for example, observed that Mexican Americans between 25 and 34 years of age were less likely to be aware of their hypertension compared with Mexican Americans between 75 and 84 years of age (odds ratio, 5.5 [95% confidence interval (CI), 1.7, 17.5], p < 0.001).

There are abundant data regarding the treatment of hypertension in the general population and in the Black population, which have resulted in the development of evidence-based treatment guidelines for these groups. [10,11] However, relatively few studies have evaluated Hispanic populations or have been adequately powered for post hoc analyses of Hispanic subsets, and no specific treatment guidelines exist for this demographic group. [12] While it is clear that antihypertensive therapy to lower BP reduces cardiovascular morbidity and mortality in all hypertensive populations, it is unclear which antihypertensive medications are safest and most effective in Hispanics. In many cases, treatment with two or more different classes of antihypertensive medications is necessary, and very few data are available about which combinations are most beneficial in Hispanics. [12] This article discusses ethnic differences in BP and cardiovascular risk factors, reviews the literature on the efficacy of antihypertensive agents in Hispanic patients, and describes the role of renin-angiotensin-aldosterone system (RAAS) inhibitors, including direct renin inhibitors (DRIs), in the treatment of Hispanic patients with hypertension. In addition to hypertension, there are high incidences of the cardiovascular disease risk factors of obesity, diabetes, and metabolic syndrome among Hispanics. [4] Several studies have shown that, compared with non-Hispanic Whites, Hispanics have a higher prevalence of these conditions and they are more likely to be diagnosed at a younger age. [2,3,7,13] This clustering of co-morbidities increases patients' overall risk of cardiovascular morbidity and mortality, and also complicates the management of hypertension. According to data from the 1999 to 2004 National Health and Nutrition Examination Survey (NHANES), more than 50% of Mexican Americans with hypertension are obese or overweight and nearly 25% are both obese or overweight and diabetic. [9] Future projections predict that over the next 10-20 years, the prevalence of obesity and diabetes in Hispanic Americans will increase at a faster rate than in non-Hispanic Whites, [14] making it even more imperative that strategies are developed to effectively manage hypertension in these patients.


## Ethnic Differences in

The prevalence of obesity, diabetes, and metabolic syndrome is particularly high among Hispanic women compared with their non-Hispanic counterparts. [4,13] The American Heart Association 2012 update on heart disease and stroke statistics reports that among Mexican-American women and non-Hispanic White women, respectively, the prevalence of diabetes is 17% versus 8%, the prevalence of metabolic syndrome is 41% versus 32%, and the proportion of women who are obese or overweight is 75% versus 59%. [4] Given the high prevalence of these co-morbid conditions, it is not surprising that only 38% of Mexican-American women treated for hypertension achieve optimal BP control, and 27% of women continue to have uncontrolled stage 2 hypertension (i.e. systolic BP ‡160 mmHg and or diastolic BP ‡100 mmHg). [9] 


## Epidemiology of Cardiovascular Disease

Several epidemiologic studies have shown that despite higher rates of obesity, diabetes, and metabolic syndrome, poorer socioeconomic status, and reduced access to health care, Hispanic ethnicity is associated with lower rates of all-cause and cardiovascular mortality compared with non-Hispanic White ethnicity. [15][16][17] Explanations for this observation, which is often referred to as the 'Hispanic Paradox,' are somewhat controversial. Some have cited misclassification of ethnicity in trials and differential ascertainment of deaths by ethnicity as possible explanations. [15,16,18,19] Others have proposed that healthselective and return immigration, positive health-related behaviors, better social support and culture-specific resiliency in Hispanic-American communities, and lower levels of subclinical cardiovascular disease contribute to these findings. [20][21][22][23][24] In contrast with the above, long-term findings from the San Antonio Heart Study refute the notion of a 'Hispanic Paradox.' [25] In this study, Mexican-American (n = 1438) and non-Hispanic White (n = 921) men and women between 45 and 64 years of age at enrollment were followed for up to 20 years to examine the relationship between ethnicity and mortality. After adjustment for age and sex, Mexican Americans had a 50% greater risk of all-cause mortality, a 60% greater risk of mortality because of coronary artery disease, and a 70% greater risk of cardiovascular mortality relative to non-Hispanic Whites. Further, even after adjusting for biomedical risk factors and socioeconomic status, these mortality hazard ratios remained above 1. [25] When mortality data from the San Antonio Heart Study were analyzed in the subset of participants with diabetes, US-born Mexican Americans (n = 554) had 66% greater risks of both all-cause and cardiovascular mortality compared with US-born non-Hispanic Whites (n = 178). [26] Diabetes and insulin use modified the mortality differential such that Mexican Americans with diabetes who did not require insulin therapy had the greatest mortality risks (figure 1). [25] Studies evaluating the prevalence of other cardiovascular and renal diseases based on ethnicity have found that Hispanics are more likely than non-Hispanic Whites to suffer from congestive heart failure [3] and end-stage renal disease. [27] Mexican-American men and women are also more likely to have higher low-density lipoprotein and triglyceride levels and lower highdensity lipoprotein levels than non-Hispanic White men, and Mexican Americans are less likely to be aware of their hypercholesterolemia than their non-Hispanic White counterparts. [4] Results of the Brain Attack Surveillance in Corpus Christi Project have also shown that stroke is more common in Mexican Americans than in non-Hispanic Whites. [28] 


## Lifestyle Factors

In the general patient population, Hispanics tend to have poorer BP control than non-Hispanics; [2,7] however, based on the results of controlled clinical trials, it is unlikely that the differences in BP control rates between Hispanics and non-Hispanics are a result of biologic differences. In controlled clinical trial settings, where external factors are equal and all patients have the same access to medical care and no-cost medication, it has been observed that BP control rates among Hispanics can be equal to or better than those of non-Hispanic Whites. [29][30][31] Thus, in many cases, lifestyle, economic, and cultural factors likely contribute to Hispanic Americans' overall level of risk for uncontrolled hypertension. Effective patient education strategies are necessary to increase awareness of risk factors associated with hypertension and to help patients learn to modify unhealthy behaviors.

As an example, according to NHANES data from 2001 to 2006, about one-third of Mexican Americans reported no participation in leisure-time physical activity. [7] This rate was twice as high as that reported in non-Hispanic Whites and 15% higher than that reported in non-Hispanic Blacks. [7] Results from the Racial and Ethnic Approaches to Community Health Across the US 2009 risk factor survey [32] showed that fruit and vegetable consumption was lower in Hispanic communities than in other ethnic minority communities throughout the USA, including non-Hispanic Black, Asian Pacific Islander, and American Indian communities. In this study, [32] Hispanics also had the lowest rates of cholesterol screenings and management of high BP with antihypertensive therapy. Acculturation and language barriers may also negatively affect access to health care and treatment in Hispanic communities. In a study of 131 277 patients in Kaiser Permanente's Northern California Diabetes Registry, Traylor and colleagues [33] found that Hispanic patients were less likely than non-Hispanic Whites to adhere to their cardiovascular medications (49% vs 58%; p < 0.001); equally, Spanish-speaking patients were less likely to adhere to their cardiovascular medications compared with English-speaking patients (51% vs 57%; p < 0.001). Eamranond and colleagues [34] observed that Hispanics with low levels of acculturation to American language, values, beliefs, and ways of life have higher rates of diabetes and hypertension, and are more likely to have poorly controlled hypercholesterolemia.

Patient trust is higher when healthcare providers are of the same ethnicity as the patient and when physicians can communicate in the patient's native language. [35] As of 2001, only 3.3% of internal medicine physicians and 3.8% of cardiologists in the USA were Hispanic, [36] suggesting that most Hispanic Americans do not have access to physicians of the same ethnicity and may choose to rely on the advice of trusted family and friends instead of healthcare professionals. Hispanics have also been shown to have a strong sense of fatalism, believing that the course of their cardiovascular disease is out of their control and making them less motivated to adopt healthy lifestyle changes, seek medical care, or adhere to treatment. [37] Physician access may also be limited by the cost of care, lack of health insurance, and limited access to regular health care. [38] According to US Census Bureau data, in 2009, per capita income for Hispanics was approximately half that of non-Hispanic Whites (US$15 063 vs US$30 941, respectively), the poverty rate among Hispanics was 25.3%, and 32.4% of Hispanics did not have health insurance compared with 12.0% of non-Hispanic Whites. [39] 3. Efficacy of Antihypertensive Agents in Hispanics:


## Review of the Literature

In landmark clinical trials of antihypertensive agents for the management of high BP and or cardiovascular disease, patients of Hispanic ethnicity have been under-represented. [12] Results from the small number of antihypertensive trials that enrolled significant numbers of Hispanic patients are also limited because ethnicity and or race were usually self-reported, [40][41][42] which may have affected the uniformity of data capture, and in most cases no distinctions were made between Hispanic Whites and Hispanic Blacks.

In an effort to identify available data from randomized controlled trials that reported on the efficacy of antihypertensive agents in Hispanic patients, a search of PubMed was conducted for English-language articles classified as clinical trials or randomized controlled trials published through 26 August 2011 using the terms ''(Hispanic * or Latino * ) and hypertension.'' This search yielded 148 articles. Analysis of these articles identified 17 [30,31,[40][41][42][43][44][45][46][47][48][49][50][51][52][53][54] publications involving 15 different studies that specifically reported on the efficacy and safety of antihypertensive agents in Hispanic patients. Additional data from the INVEST study (table I provides full names of trial acronyms used in this article) was also included from a publication not identified in this search. [29] In addition, the author was aware of and included relevant data from four studies that were presented as abstracts [55][56][57][58] at scientific meetings. The main results from all identified articles (n = 18) and abstracts (n = 4) presenting data from 19 studies are summarized in table II. [29][30][31][40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58] Only two of the studies identified were outcomes trials that reported results for the subset of Hispanic participants: AEs were comparable between treatment groups and mostly mild or moderate in severity (actual data not reported)

Ofili and colleagues [53] Randomized ALLHAT [30] and INVEST. [29,31] Of these, only INVEST reported statistical comparisons of efficacy in the Hispanic cohort compared with the non-Hispanic cohorts. [29,31] INVEST was an important trial because it provided evidence-based findings on the efficacy of antihypertensive agents in Hispanic patients compared with non-Hispanic patients. When hypertensive patients with coronary artery disease were treated with either calcium channel blocker (CCB)-based therapy (verapamil + trandolapril) or b-adrenoceptor antagonist (b-blocker)-based therapy (atenolol + diuretic), Hispanic patients achieved better BP control than non-Hispanic patients, and Hispanic patients had a significantly lower risk of experiencing adverse cardiovascular outcomes, including non-fatal myocardial infarction, non-fatal stroke, or death (figure 2). Addition of an angiotensinconverting enzyme (ACE) inhibitor to CCB therapy was associated with a decreased risk of new-onset diabetes in Hispanic patients, while increasing doses of b-blocker and diuretic therapy increased the risk of new-onset diabetes. [29] Results of a separate analysis of women participating in the INVEST trial [31] were similar to those of the overall study population. [29] Hispanic women receiving antihypertensive therapy were more likely to achieve BP control compared with non-Hispanic White women (75% vs 68%, respectively; p < 0.001), and Hispanic women were less likely to experience non-fatal myocardial infarction, non-fatal stroke, or all-cause death compared with non-Hispanic White women (5.7% vs 12.3%, respectively; adjusted hazard ratio, 0.84 [95% CI 0.71, 0.98]). [31] The majority ( ‡79%) of both Hispanic and non-Hispanic patients in the INVEST trial required multiple agents to achieve BP goals, [29,31] and this finding is similar to what has been shown in other studies of populations with high levels of cardiovascular risk. [59] In the ALLHAT study, hypertensive patients with at least one other coronary heart disease risk factor were randomized to receive an ACE inhibitor, a CCB, an a 1 -blocker, or a thiazide diuretic, with step-up to combination therapy as necessary. [30] In an analysis of the effects of Hispanic ethnicity on study results, Margolis and colleagues [30] observed that Hispanic patients were less likely than non-Hispanics to have controlled BP (<140 90 mm Hg) at baseline, but within 6-12 months of followup, the proportion of Hispanic patients with controlled BP exceeded that of non-Hispanics. At 4 years of follow-up, BP was controlled in 72% of Hispanic Whites, 69% of Hispanic Blacks, 67% of non-Hispanic Whites, and 59% of non-Hispanic Blacks. Thus, the authors of this study concluded that Hispanic ethnicity was not associated with inferior BP control when patients had equal access to medications and health care at no cost. [30] [55] (abstract) Between-group differences in SBP change and BP goal rates were significant for Whites and Blacks but not Hispanics

Safety not reported for Hispanics ASCENT [58] (abstract) 


## Management of Hypertension in Hispanic Patients

Results from non-cardiovascular outcomes, BP-lowering efficacy trials identified from the search are also summarized in table II. [40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58] In general, all of the different classes of antihypertensive drugs substantially reduced BP in Hispanic patients, and greater BP reductions were observed with combination therapy than with monotherapy. In most cases, a RAAS inhibitor (ACE inhibitor, angiotensin II receptor blocker [ARB], or DRI) was used, either alone or in combination with another antihypertensive agent.


## Benefits of Renin-Angiotensin-Aldosterone System Inhibitor Therapy

RAAS inhibitors may be more beneficial than other classes of antihypertensive therapy in reducing complications related to obesity, diabetes, and metabolic syndrome, which as discussed previously are significant concerns for many Hispanic patients. [60] Over-activation of the RAAS results in increased vasoconstriction, increased sodium reabsorption, and increased aldosterone secretion, all of which elevate BP. In addition, increased RAAS activity can contribute to the pathophysiology of diabetes and metabolic syndrome. Increased aldosterone production has been shown to impair insulin signaling and increase insulin resistance, and angiotensin II-mediated oxidative stress can damage pancreatic islet cells. [60,61] Excess food intake has also been linked to increased angiotensin II formation in adipocytes, and body mass index is positively correlated with plasma aldosterone and plasma renin activity levels, suggesting a pathophysiologic association between RAAS activation and obesity. [60] Therefore, in addition to lowering BP, antihypertensive therapy with RAAS inhibitors may also improve glucose metabolism and delay or prevent the onset of diabetes. [60,61] RAAS inhibitors have also been shown to reduce tissue injury and microvascular damage in patients with hypertension and hyperglycemia. [62] For these reasons, RAAS inhibitors are an appropriate component of first-line therapy in hypertensive patients at risk for obesity, diabetes, and or metabolic syndrome. [60] 


### Angiotensin-Converting Enzyme (ACE) Inhibitors

Data from randomized controlled trials reporting on the BP-lowering efficacy of ACE inhibitors in Hispanic patients are very limited. In a study examining the effects of dietary salt intake on the efficacy of the ACE inhibitor enalapril or the CCB isradipine, when Hispanic patients consumed more than 190 mmol of sodium per day, treatment with enalapril reduced BP by -11.4 -9.6 mmHg and treatment with isradipine reduced BP by -13.7 -8.9 mmHg compared with placebo. When Hispanic patients consumed 88 mmol or less of sodium per day, treatment with enalapril reduced BP by -13.3 -7.5 mmHg and treatment with isradipine reduced BP by -10.0 -6.0 mmHg compared with placebo. [50] Although the ALLHAT trial included the ACE inhibitor lisinopril as one of four assigned treatments, [30] analysis of the efficacy of the different classes of drugs (i.e. ACE inhibitor, CCB, a 1 -blocker, or a thiazide diuretic) in Hispanic patients has not been reported. In the ATTAIN trial, [63] (discussed further in the DRI section below), treatment with the ACE inhibitor ramipril reduced mean sitting BP by -20.1 -4.9 mmHg in Hispanic patients (n = 29), and 44.8% of these patients achieved BP control. [55] Further studies are necessary to adequately evaluate the efficacy of ACE inhibitor monotherapy or combination therapy in Hispanic patients.


### Angiotensin II Receptor Blockers (ARBs)

Several studies were identified that reported the efficacy of ARB monotherapy or combination therapy in Hispanic patients. These studies indicate that substantial proportions of Hispanic patients treated with ARBs as part of their treatment regimen can achieve BP goals. The largest, TRINITY (NCT00654745; complete results posted on ClinicalTrials.gov), [64] included a prespecified subgroup analysis of 369 Hispanic Latino and 2122 non-Hispanic non-Latino hypertensive patients that has Reprinted from Cooper-DeHoff et al. [29] , with permission from Elsevier. MI = myocardial infarction.

been published in abstract form. [56] Regardless of ethnicity, triple therapy with olmesartan amlodipine hydrochlorothiazide (HCTZ) resulted in significantly (p < 0.05) greater reductions in systolic BP relative to dual therapy with olmesartan amlodipine, olmesartan HCTZ, or amlodipine HCTZ. [56,64] At 12 weeks, 57% of Hispanic Latino participants in the triple-therapy group versus 41-51% in the dual-therapy groups achieved BP goals (<140 90 mmHg or <130 80 mmHg for those with diabetes or chronic renal or cardiovascular disease). In non-Hispanics non-Latinos, the corresponding results were 66% versus 34-47%. [56] In the INCLUSIVE trial, after 18 weeks of treatment with irbesartan HCTZ, 70% of non-Hispanic Whites, 66% of non-Hispanic Blacks, and 65% of Hispanics achieved BP goals. [42] The Val-MARC study comparing valsartan versus valsartan HCTZ found that in Hispanic patients with stage 2 hypertension, combination therapy lowered systolic BP by -21.7 mmHg, compared with -16.3 mmHg with monotherapy. [51] Similarly, the EVALUATE trial showed that combination therapy with either valsartan HCTZ or amlodipine HCTZ effectively lowered BP in Hispanic patients with stage 2 hypertension (reductions of -17.9 -9.7 mmHg and -14.2 -7.2 mmHg, respectively). [41] In a study evaluating triple therapy with amlodipine valsartan HCTZ 10 320 12.5 mg in Hispanic patients, 8 weeks of treatment reduced mean systolic BP by -36.7 mmHg in Hispanic patients and 73% of patients achieved target BP <140 90 mmHg. [53] 3.


## Direct Renin Inhibitors (DRIs)

The only DRI currently approved for the treatment of hypertension, either as monotherapy or in combination with other antihypertensive agents, is aliskiren. In clinical studies, aliskiren monotherapy and combination therapy with other agents (e.g. diuretics or amlodipine) have all been shown to significantly reduce BP and plasma renin activity in patients with stage 1 or stage 2 hypertension. [63,[65][66][67] There are currently no cardiovascular outcomes data available on the use of aliskiren in Hispanic patients, and BP-lowering data are limited to subgroup analyses from clinical trials. Three subgroup analyses [55,57,58] on the BP-lowering efficacy of aliskiren monotherapy or combination therapy with HCTZ in Hispanics were reported in the form of abstracts. In the 12-week ACQUIRE study (NCT00705575; complete results posted on ClinicalTrials.gov), [66] Hispanic patients had mean BP reductions of -35.8 -15.8 mmHg with aliskiren HCTZ and -23.4 -9.5 mmHg with aliskiren monotherapy. [57] In the ATTAIN study (NCT00772577; complete results posted on ClinicalTrials.gov), [55,63] 8 weeks of treatment with aliskiren HCTZ reduced BP by -27.7 -10.7 mmHg in Hispanic patients, compared with -20.1 -4.9 mmHg with ramipril monotherapy (p < 0.004 between treatment groups for change in diastolic BP). [55] In the 8-week ASCENT study (NCT00942994; complete results posted on ClinicalTrials.gov), [67] self-identified Hispanic patients had least-square mean systolic BP reductions of -37.1 mmHg with aliskiren amlodipine HCTZ versus -27.5 mmHg with aliskiren amlodipine (p < 0.0001). [58] Corresponding results for diastolic BP were -14.7 mmHg versus -11.0 mmHg (p = 0.0054). [58] 


## Considerations for Treating the Hypertensive Hispanic Patient

For most patients, regardless of ethnicity, multiple antihypertensive agents are needed to attain BP goal. [59] For example, current guidelines from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [10] state that two or more antihypertensive medications are usually required to achieve BP goals in patients with diabetes and chronic kidney disease, and for patients whose BP is more than 20 mmHg above the systolic BP goal or more than 10 mmHg above the diastolic BP goal. For these patients, current guidelines recommend initiation of therapy with two agents, one of which is usually a thiazide diuretic. The choice of a thiazide diuretic as part of an initial treatment regimen is based on the well established observations that drugs in this class are generally well tolerated, can prevent cardiovascular complications associated with hypertension, and are usually cost effective. [10] The combination of a diuretic with a RAAS inhibitor is often recommended as first-line therapy in patients with stage 2 hypertension, given that the RAAS is the central mediator of the majority of hypertension-related complications and that the RAAS is activated in response to pressure-related target-organ damage. [10,11] Compelling indications for RAAS-inhibitorbased combination treatment regimens in the general population include co-morbid cardiovascular disease, diabetes, chronic kidney disease, stroke prevention, heart failure, and coronary artery disease risk. [10] Although data evaluating the efficacy of RAAS-inhibitor-based therapy in Hispanics are limited, the high prevalence of obesity, diabetes, and metabolic syndrome in this population provides rationale for the use of this class of antihypertensive drugs.

When treating hypertension in the Hispanic patient, physicians should be aware of the typical cardiovascular clustering that is common in this ethnic group and the treatment challenges that this creates. Results from the INVEST study suggest that combination therapy is necessary for the majority of hypertensive Hispanic patients with coronary artery disease to achieve target BP goals and that achieving these BP goals is associated with significantly lower risks of adverse cardiovascular events. [29] 


## Summary and Conclusions

Hypertension control and hypertension-related co-morbidities are substantial problems in the US Hispanic population. Given that Hispanics are the fastest growing and youngest ethnic population in the USA, strategies to prevent hypertensionrelated morbidity and mortality are essential, including hypertension education programs and attention to economic issues when prescribing to this demographic group. Aggressive antihypertensive strategies are needed; however, not enough has been done to include Hispanic Americans in clinical studies in sufficient representative numbers. Therefore, very little evidencebased information is available in this population, and current guidelines do not provide specific guidance for treating hypertension in Hispanic patients. Given the clustering of hypertension with obesity, diabetes, and metabolic syndrome in Hispanics and the role of the RAAS in the pathogenesis of these conditions, RAAS-based treatments should be a cornerstone of therapy. Studies that included subgroup analyses of Hispanic patients have shown that treatment with RAAS inhibitors in combination with other antihypertensive agents is associated with substantial BP lowering; however, more data are needed to determine whether RAAS-based treatment regimens improve cardiovascular outcomes in this growing patient population.


= ambulatory BP; ACE = angiotensin-converting enzyme; AE = adverse event; ARB = angiotensin II receptor blocker; BP = blood pressure; CABG = coronary artery bypass graft; CCB = calcium-channel blocker; CI = confidence interval; DBP = diastolic BP; DRI = direct renin inhibitor; ER = extended release; HCTZ = hydrochlorothiazide; HF = heart failure; HR = hazard ratio; IR = immediate release; MI = myocardial infarction; NS = not significant; PCI = percutaneous coronary intervention; RAAS = renin-angiotensin-aldosterone system; SBP = systolic blood pressure; SR = slow release; TIA = transient ischemic attack.

## Fig. 2 .
2INVEST (International Verapamil SR Trandolapril Study): Kaplan-Meier survival curve of time to primary outcome event (composite of death, non-fatal myocardial infarction, or non-fatal stroke) by Hispanic status.


Cardiovascular Disease Risk Factors, the Epidemiology of Cardiovascular Disease, and Lifestyle Factors 2.1 Cardiovascular Disease Risk Factors: Obesity, Diabetes, and Metabolic Syndrome

## Table I .
IFull trial names of study acronyms used in this article TRINITY Triple Therapy with Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide in Hypertensive Patients Study Val-MARC Valsartan-Managing Blood Pressure Aggressively and Evaluating Reductions in High-Sensitivity C-Reactive Protein Table II. Studies reporting on the efficacy of antihypertensive agents in the Hispanic population (PubMed findings) Study reference Design No. of Hispanic patients Daily treatment Duration Main findings in Hispanics at endpointAcronym 
Name 

ACQUIRE 
Aliskiren Alone or in Combination With Hydrochlorothiazide in 
Patients With Stage 2 Hypertension to Provide Quick Intensive 
Control of Blood Pressure 

ALLHAT 
Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack Trial 

ASCENT 
Aliskiren+Amlodipine+HCTZ in Minority Patients With Stage 2 
Hypertension 

ATTAIN 
Aliskiren HCTZ vs Ramipril in Obese Patients with Stage 2 
Hypertension 

EVALUATE Evaluation of Valsartan's Uniqueness and 24-Hour Blood 
Pressure Efficacy 

INCLUSIVE Irbesartan HCTZ Blood Pressure Reductions in Diverse 
Patient Populations 

INVEST 
International Verapamil SR Trandolapril Study 

Outcomes trials 
INVEST [29,31] 

Randomized, open-

label in hypertensive 
patients with 
coronary artery 
disease 

8045 (14 531 non-
Hispanics), including 

5107 Hispanic women 
(4710 non-Hispanic white 
women) 
Verapamil SR 240 mg or atenolol 

50 mg; other drugs added if 
needed to achieve BP goal 

2 years 
At baseline, Hispanics had a higher prevalence of angina pectoris 
and diabetes vs non-Hispanics and a lower prevalence of MI, 
CABG PCI, stroke TIA, unstable angina, HF, and 
hypercholesterolemia 

Baseline BP: 148 87 mmHg in Hispanics and 151 86 mmHg in 
non-Hispanics 

In Hispanics vs non-Hispanics, either treatment strategy resulted 
in greater SBP reduction (-21.3 mmHg vs 

-17.4 mmHg; p 

< 0.001) 

and lower risk for experiencing the primary outcome of death, 
non-fatal MI, or non-fatal stroke (HR 0.87; 95% CI 0.78, 0.97); 
analysis in women showed similar findings 

Hispanic ethnicity was associated with an increased risk of 
new-onset diabetes (HR 1.19; 95% CI 1.04, 1.36), though treatment 

with trandolapril in the verapamil SR strategy reduced the risk 

ALLHAT [30] 

Randomized, 
double-blind in 
hypertension with 

 ‡1 coronary heart 
disease risk factor 
5239 Hispanic Whites 
and 1090 Hispanic 
Blacks (15 705 non-
Hispanic Whites and 

10 608 non-Hispanic 
Blacks) 

Chlorthalidone 12.5-25 mg, 

amlodipine 2.5-10 mg, lisinopril 

10-40 mg, or doxazosin 2-8 mg; 
other drugs added if needed to 
achieve BP goal 

4 years 
At baseline, Hispanics had more diabetes mellitus, less 
atherosclerotic disease, and were slightly younger than 
non-Hispanic Whites 

Baseline BP 144.5-146.7 81.8-87.1 mmHg across ethnic groups 
At baseline, Hispanics were less likely to have BP controlled 
(<140 90 mmHg), but by 6 months, BP control among Hispanics was 
similar to or higher than that of non-Hispanics 

At 4 years, BP goal (<140 90 mmHg) was achieved by 72% of 
Hispanic Whites, 69% of Hispanic Blacks, 67% of non-Hispanic 
Whites, and 59% of non-Hispanic Blacks 

BP-lowering efficacy trials not involving RAAS inhibitors 
b-Blocker 

Punzi and 
colleagues [40] 

Randomized, 
double-blind in stage 

1 or 2 hypertension 

277 
Titration up to nebivolol 40 mg or 
placebo 

8 weeks 
Baseline BP: 155.8 100.3 mmHg for nebivolol and 
156.5 100.6 mmHg for placebo 

BP was reduced by 
-14.1 -11.1 mmHg with nebivolol and 

-9.3 -7.3 mmHg with placebo (p 

£ 0.001) 

AE rates were 17% with nebivolol and 22% with placebo 

CCB 
Herrera and 
colleagues [43] 

Randomized, 
double-blind in stage 

1 or 2 hypertension 

118 
Titration up to diltiazem 300 mg or 
placebo 

8 weeks 
Baseline BP: 148.7 98.6 mmHg for diltiazem and 
153.6 99.8 mmHg for placebo 

BP was reduced by 
-7.8 -8.2 mmHg with diltiazem and 

-0.1 -4.1 mmHg with placebo (p 

< 0.01) 

Treatment-related AE rates were 15% for diltiazem and 19% 
for placebo 

Continued next page 
Table II. 

Contd 

Study reference Design 
No. of Hispanic patients Daily treatment 

Duration Main findings in Hispanics at endpoint 

Prisant and 
colleagues [44] 

Open-label 
(randomized dose) 

in stage 1 or 2 
hypertension 
101 (1700 Whites and 
466 Blacks) 
Titration up to verapamil 400 mg as 
chronotherapy 

12 weeks 
Baseline BP: 156.8 94.7 mmHg in Hispanics, 155.1 94.2 mm Hg 
in Whites, 154.1 96.6 mmHg in Blacks 
Target BP (<140 90 mm Hg) was achieved by 58% of Hispanics, 
63% of Whites, and 60% of Blacks 
AE rates were similar across all ethnic groups; the most common 
AE was constipation (31%) 

Black and 
colleagues [45] 

Randomized, 
double-blind in stage 

1 isolated 
hypertension 
51 (84 Whites and 
21 Blacks) 

Felodipine ER 2.5-10 mg or 
placebo 

1 year 
Baseline BP: 149 83 mmHg for felodipine and 150 84 mmHg for 
placebo 

Overall, BP was reduced by 
-11.7 -3.0 mmHg with felodipine and 

by 
-2.0 -0.1 with placebo (p 

< 0.01) 

Subgroup analyses showed that significant BP reductions were 
achieved with felodipine vs placebo regardless of ethnicity 

Fuenmayor and 
colleagues [46,47] 

Randomized, open-

label, 2-way 
crossover in mild to 
moderate 
uncomplicated 
hypertension 

30 

Verapamil IR or verapamil SR 
240-480 mg 

8 days 
per 
treatment 
Baseline BP range: 153-160 108-110 mmHg across all treatment 
groups 

Maximum BP change was 
-34 -27 mmHg for both verapamil IR 

and verapamil SR 480 mg 
73% of patients treated with verapamil SR 240 mg and 83% of 
patients treated with verapamil SR 480 mg achieved normotension 

Incidence of AEs was dose dependent; 73% of patients treated 
with verapamil 480 mg reported headache, palpitations, flushing, 
and or tiredness 

a 
2 -Agonist or 

a 
1 -antagonist 

Dias and 
colleagues [48] 
Open-label in stage 

1 or 2 hypertension 

73 (280 Blacks) 

Titrated up to clonidine 0.3 mg 
(transdermal patch) 

12 weeks 
Baseline BP: 158.5 99.5 mmHg 
BP was reduced by~16 13 mmHg in Hispanics and~15 12 mmHg 
in Blacks (numbers estimated from graph) 
Overall AE rate was 21% 

Harris and 
Alvarez [49] 

Randomized, 
double-blind in stage 

1 or 2 hypertension 

34 (44 total) 

Titrated up to clonidine 0.3 mg 
(transdermal patch) or terazosin 

5 mg (oral) 

8 weeks 
Baseline BP: 156.0 100.6 mmHg for clonidine and 154.0 100.3 for 
terazosin 

Overall, BP was reduced by 
-10.2 -11.6 mmHg with clonidine and 

by 
-7.1 -9.6 mmHg with terazosin (p 

= NS) 

Overall AE rates were 30% with clonidine and 48% with terazosin 

BP-lowering efficacy trials involving RAAS inhibitors 

ACE inhibitor 
Weir and 
colleagues [50] 

Salt-sensitive 

patients with stage 

1-2 hypertension 

63 (232 White and 
96 Black) 

Enalapril 10-40 mg, isradipine 
10-20 mg or placebo; alternating 
high-and low-salt diet 

20 weeks 
BP difference between enalapril and placebo on high-salt diet: 
-11.4 -9.6 mmHg in Hispanics, 
-15.0 -10.9 mmHg for Whites, and 

-10.3 -8.6 mmHg for Blacks; on low-salt diets: 

-13.3 -7.5 mmHg for 

Hispanics, 
-12.7 -9.0 mmHg for Whites, and 

-7.7 -5.5 mmHg for 

Blacks 

Continued next page 
Table II. 

Contd 

Study reference Design 
No. of Hispanic patients Daily treatment 

Duration Main findings in Hispanics at endpoint 
BP difference between isradipine and placebo on high-salt diet: 
-13.7 -8.9 mmHg in Hispanics, 
-14.8 -9.4 mmHg for Whites, and 

-15.9 -12.1 mm Hg for Blacks; on low-salt diets: 

-10.0 -6.0 mmHg 

for Hispanics, 
-7.6 -4.2 mmHg for Whites, and 

-7.1 -5.9 mmHg for 

Blacks 

Controlling for salt sensitivity decreased ethnicity-related 
differences in antihypertensive efficacy of enalapril and isradipine 

ATTAIN [55] 
(abstract) 
See results under DRI section below 

ARB 
TRINITY [56] 
(abstract) 

Randomized, 
double-blind in stage 

1 or 2 hypertension 

369 (2122 non-
Hispanic non-Latino) 

Olmesartan amlodipine HCTZ 

40 mg 10 25 mg, 
olmesartan amlodipine 

40 mg 10 mg, olmesartan HCTZ 
40 mg 25 mg, or amlodipine HCTZ 
10 mg 25 mg 

12 weeks 
BP was reduced to a significantly greater extent (p 

< 0.05) in the 

triple-therapy group vs the dual-therapy groups (actual BP 

values reductions not reported) 

57% of Hispanic Latino patients treated with triple therapy vs 
41-51% with dual therapy achieved BP 

<140 90 mmHg 

(<130 80 mmHg if diabetic or with chronic renal or cardiovascular 
disease) 



## Table II .
IIContd 

Study reference Design 
No. of Hispanic patients Daily treatment 

Duration Main findings in Hispanics at endpoint 

ATTAIN 
Adis ª 2012 Springer International Publishing AG. All rights reserved.Am J Cardiovasc Drugs 2012; 12(3)
AcknowledgmentsTechnical assistance with editing, figure preparation, and styling of the manuscript for submission was provided by Cherie Koch, PhD, and Michael S. McNamara, MS, of Oxford PharmaGenesis Inc., and was funded by Novartis Pharmaceuticals Corporation. The author was fully responsible for all content and editorial decisions and received no financial support or other form of compensation related to the development of this manuscript. The opinions expressed in the manuscript are those of the author, and Novartis Pharmaceuticals Corporation had no influence on the contents.Author disclosure: Dr Guzman has served as a Consultant and faculty member for Novartis Pharmaceuticals Corporation.
Hispanics in the United States. US Census Bureau. Hispanics in the United States. US Census Bureau [online]. Available from URL: http://www.census.gov/population/www/socdemo/hispanic/files/Internet_ Hispanic_in_US_2006.pdf [Accessed 2011 Aug 17]

Heart failure in Hispanics. R P Vivo, S R Krim, C Cevik, J Am Coll Cardiol. 53Vivo RP, Krim SR, Cevik C, et al. Heart failure in Hispanics. J Am Coll Cardiol 2009; 53: 1167-75

Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. H Bahrami, R Kronmal, D A Bluemke, Arch Intern Med. 168Bahrami H, Kronmal R, Bluemke DA, et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med 2008; 168: 2138-45

Heart disease and stroke statistics-2012 update: a report from the. V L Roger, Go As, D M Lloyd-Jones, American Heart Association. Circulation. 125Roger VL, Go As, Lloyd-Jones DM, et al. Heart disease and stroke sta- tistics-2012 update: a report from the American Heart Association. Circu- lation 2012; 125: e2-20

Hypertension in America: estimates for the US civilian noninstitutionalized population, age 18 and older. W Carroll, Rockville, MDAgency for Healthcare Research and QualityCarroll W. Hypertension in America: estimates for the US civilian non- institutionalized population, age 18 and older, 2008. Agency for Healthcare Research and Quality, Rockville, MD [online]. Available from URL: http://www. meps.ahrq.gov/mepsweb/data_files/publications/st315/stat315.shtml [Accessed 2011 Aug 17]

Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. A P Carson, G Howard, G L Burke, Hypertension. 57Carson AP, Howard G, Burke GL, et al. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension 2011; 57: 1101-7

Health behaviors and racial disparity in blood pressure control in the National Health and Nutrition Examination Survey. N Redmond, H J Baer, L S Hicks, Hypertension. 57Redmond N, Baer HJ, Hicks LS. Health behaviors and racial disparity in blood pressure control in the National Health and Nutrition Examination Survey. Hypertension 2011; 57: 383-9

Hypertension-related mortality among Hispanic subpopulations -United States. MMWR Morb Mortal Wkly Rep. 55Hypertension-related mortality among Hispanic subpopulations -United States, 1995-2002. MMWR Morb Mortal Wkly Rep 2006; 55: 177-80

Predictors of hypertension awareness, treatment, and control among Mexican American women and men. A Bersamin, R S Stafford, M A Winkleby, J Gen Intern Med. 24SupplBersamin A, Stafford RS, Winkleby MA. Predictors of hypertension aware- ness, treatment, and control among Mexican American women and men. J Gen Intern Med 2009; 24 Suppl. 3: 521-7

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. A V Chobanian, G L Bakris, H R Black, Hypertension. 42Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint Na- tional Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52

Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. J M Flack, D A Sica, G Bakris, Hypertension. 56Flack JM, Sica DA, Bakris G, et al. Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement. Hypertension 2010; 56: 780-800

Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. I U Park, A L Taylor, Ann Fam Med. 5Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to pre- vent cardiovascular outcomes: a systematic review. Ann Fam Med 2007; 5: 444-52

Differences in prevalence of obesity among black, white, and Hispanic adults -United States. MMWR Morb Mortal Wkly Rep. 58Differences in prevalence of obesity among black, white, and Hispanic adults - United States, 2006-2008. MMWR Morb Mortal Wkly Rep 2009; 58: 740-4

Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Y Wang, M A Beydoun, L Liang, Obesity (Silver Spring). 16Wang Y, Beydoun MA, Liang L, et al. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity (Silver Spring) 2008; 16: 2323-30

Mortality by Hispanic status in the United States. P D Sorlie, E Backlund, N J Johnson, JAMA. 270Sorlie PD, Backlund E, Johnson NJ, et al. Mortality by Hispanic status in the United States. JAMA 1993; 270: 2464-8

Evaluation of mortality data for older Mexican Americans: implications for the Hispanic paradox. K V Patel, K Eschbach, L A Ray, Am J Epidemiol. 159Patel KV, Eschbach K, Ray LA, et al. Evaluation of mortality data for older Mexican Americans: implications for the Hispanic paradox. Am J Epidemiol 2004; 159: 707-15

Coronary heart disease and stroke deaths -United States. N L Keenan, K M Shaw, MMWR Surveill Summ. 60SupplKeenan NL, Shaw KM. Coronary heart disease and stroke deaths -United States, 2006. MMWR Surveill Summ 2011; 60 Suppl.: 62-6

Quality of death rates by race and Hispanic origin: a summary of current research. H M Rosenberg, J D Maurer, P D Sorlie, Vital Health Stat. 2Rosenberg HM, Maurer JD, Sorlie PD, et al. Quality of death rates by race and Hispanic origin: a summary of current research, 1999. Vital Health Stat 2 1999; 1-13

Rethinking the Hispanic paradox: death rates and life expectancy for US non-Hispanic White and Hispanic populations. D P Smith, B S Bradshaw, Am J Public Health. 96Smith DP, Bradshaw BS. Rethinking the Hispanic paradox: death rates and life expectancy for US non-Hispanic White and Hispanic populations. Am J Public Health 2006; 96: 1686-92

Do Mexican Americans really have low rates of cardiovascular disease. M P Stern, M Wei, Prev Med. 296Pt 2Stern MP, Wei M. Do Mexican Americans really have low rates of cardio- vascular disease? Prev Med 1999; 29 (6 Pt 2): S90-5

Understanding the Hispanic paradox. L Franzini, J C Ribble, A M Keddie, Ethn Dis. 11Franzini L, Ribble JC, Keddie AM. Understanding the Hispanic paradox. Ethn Dis 2001; 11: 496-518

Do healthy behaviors decline with greater acculturation? Implications for the Latino mortality paradox. A F Abraı´do-Lanza, M T Chao, K R Flo´rez, Soc Sci Med. 61Abraı´do-Lanza AF, Chao MT, Flo´rez KR. Do healthy behaviors decline with greater acculturation? Implications for the Latino mortality paradox. Soc Sci Med 2005; 61: 1243-55

Do differences in subclinical cardiovascular disease in Mexican Americans versus European Americans help explain the Hispanic paradox?. J M Gardin, Z Allebban, N D Wong, Am J Cardiol. 105Gardin JM, Allebban Z, Wong ND, et al. Do differences in subclinical cardiovascular disease in Mexican Americans versus European Americans help explain the Hispanic paradox? Am J Cardiol 2010; 105: 205-9

Resiliency in the face of disadvantage: do Hispanic cultural characteristics protect health outcomes?. L C Gallo, F J Penedo, K Espinosa De Los Monteros, J Pers. 77Gallo LC, Penedo FJ, Espinosa de los Monteros K, et al. Resiliency in the face of disadvantage: do Hispanic cultural characteristics protect health out- comes? J Pers 2009; 77: 1707-46

All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio Heart Study: evidence against the ''Hispanic paradox. K J Hunt, R G Resendez, K Williams, Am J Epidemiol. 158Hunt KJ, Resendez RG, Williams K, et al. All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older partic- ipants in the San Antonio Heart Study: evidence against the ''Hispanic par- adox''. Am J Epidemiol 2003; 158: 1048-57

All-cause and cardiovascular mortality among diabetic participants in the San Antonio Heart Study: evidence against the ''Hispanic Paradox. K J Hunt, K Williams, R G Resendez, Diabetes Care. 25Hunt KJ, Williams K, Resendez RG, et al. All-cause and cardiovascular mortality among diabetic participants in the San Antonio Heart Study: evi- dence against the ''Hispanic Paradox''. Diabetes Care 2002; 25:1557-63

Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemma. Palmer Alves, T Lewis, J , Clin Nephrol. 74Suppl. 1Palmer Alves T, Lewis J. Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and eco- nomic dilemma. Clin Nephrol 2010; 74 (Suppl. 1): S72-7

Excess stroke in Mexican Americans compared with non-Hispanic whites: the Brain Attack Surveillance in Corpus Christi Project. L B Morgenstern, M A Smith, L D Lisabeth, Am J Epidemiol. 160Morgenstern LB, Smith MA, Lisabeth LD, et al. Excess stroke in Mexican Americans compared with non-Hispanic whites: the Brain Attack Surveil- lance in Corpus Christi Project. Am J Epidemiol 2004; 160: 376-83

Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients: findings from the International Verapamil SR Trandolapril Study (INVEST). R M Cooper-Dehoff, Aranda Jr, J M Gaxiola, E , Am Heart J. 151Cooper-DeHoff RM, Aranda Jr JM, Gaxiola E, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients: findings from the International Verapamil SR Trandolapril Study (INVEST). Am Heart J 2006; 151: 1072-9

Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. K L Margolis, L B Piller, C E Ford, Hypertension. 50Margolis KL, Piller LB, Ford CE, et al. Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2007; 50: 854-61

Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST. R M Cooper-Dehoff, Q Zhou, E Gaxiola, J Womens Health (Larchmt ). 16Cooper-DeHoff RM, Zhou Q, Gaxiola E, et al. Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST. J Womens Health (Larchmt ) 2007; 16: 632-40

Surveillance of health status in minority communities-Racial and Ethnic Approaches to Community Health Across the. Y Liao, D Bang, S Cosgrove, MMWR Surveill Summ. 60Liao Y, Bang D, Cosgrove S, et al. Surveillance of health status in minority communities-Racial and Ethnic Approaches to Community Health Across the U.S. (REACH U.S.) Risk Factor Survey, United States, 2009. MMWR Surveill Summ 2011; 60: 1-44

Adherence to cardiovascular disease medications: does patient-provider race ethnicity and language concordance matter?. A H Traylor, J A Schmittdiel, C S Uratsu, J Gen Intern Med. 25Traylor AH, Schmittdiel JA, Uratsu CS, et al. Adherence to cardiovascular disease medications: does patient-provider race ethnicity and language con- cordance matter? J Gen Intern Med 2010; 25: 1172-7

Acculturation and cardiovascular risk factor control among Hispanic adults in the United States. P P Eamranond, C C Wee, A T Legedza, Public Health Rep. 124Eamranond PP, Wee CC, Legedza AT, et al. Acculturation and cardiovascular risk factor control among Hispanic adults in the United States. Public Health Rep 2009; 124: 818-24

Prevention and control of coronary heart disease and stroke -nomenclature for prevention approaches in public health: a statement for public health practice from the Centers for Disease Control and Prevention. G A Mensah, W H Dietz, V B Harris, Am J Prev Med. 29Mensah GA, Dietz WH, Harris VB, et al. Prevention and control of coronary heart disease and stroke -nomenclature for prevention approaches in public health: a statement for public health practice from the Centers for Disease Control and Prevention. Am J Prev Med 2005; 29: 152-7

Working group 3: How to encourage more minorities to choose a career in cardiology. C K Francis, J S Alpert, L T Clark, J Am Coll Cardiol. 44Francis CK, Alpert JS, Clark LT, et al. Working group 3: How to encourage more minorities to choose a career in cardiology. J Am Coll Cardiol 2004; 44: 241-5

Adherence to diabetes selfcare behaviors in English-and Spanish-speaking Hispanic men. L O Rustveld, V N Pavlik, M L Jibaja-Weiss, Patient Prefer Adherence. 3Rustveld LO, Pavlik VN, Jibaja-Weiss ML, et al. Adherence to diabetes self- care behaviors in English-and Spanish-speaking Hispanic men. Patient Prefer Adherence 2009; 3: 123-30

Racial and ethnic disparity in blood pressure and cholesterol measurement. S H Stewart, M D Silverstein, J Gen Intern Med. 17Stewart SH, Silverstein MD. Racial and ethnic disparity in blood pressure and cholesterol measurement. J Gen Intern Med 2002; 17: 405-11

Income, Poverty, and Health Insurance Coverage in the United States. C Denavas-Walt, B D Proctor, Jc U S Smith, Bureau, Current Population Reports. 2010Government Printing OfficeDeNavas-Walt C, Proctor BD, Smith JC. U.S. Census Bureau, Current Pop- ulation Reports, P60-238, Income, Poverty, and Health Insurance Coverage in the United States: 2009, U.S. Government Printing Office, Washington, DC: 2010

Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. H Punzi, A Lewin, T Lukic, Ther Adv Cardiovasc Dis. 4Punzi H, Lewin A, Lukic T, et al. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. Ther Adv Cardiovasc Dis 2010; 4: 349-57

24-Hour ambulatory blood pressure response to combination valsartan hydrochlorothiazide and amlodipine hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVAL-UATE study. Wright Jr, J T Lacourcie`re, Y Samuel, R , J Clin Hypertens (Greenwich ). 12Wright Jr JT, Lacourcie`re Y, Samuel R, et al. 24-Hour ambulatory blood pressure response to combination valsartan hydrochlorothiazide and amlo- dipine hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVAL- UATE study. J Clin Hypertens (Greenwich ) 2010; 12: 833-40

Irbesartan HCTZ fixed combinations in patients of different racial ethnic groups with uncontrolled systolic blood pressure on monotherapy. E O Ofili, K C Ferdinand, E Saunders, J Natl Med Assoc. 98Ofili EO, Ferdinand KC, Saunders E, et al. Irbesartan HCTZ fixed combina- tions in patients of different racial ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006; 98: 618-26

Long-acting diltiazem CD is safe and effective in a hypertensive Mexican-American population. C R Herrera, A Lewin, R Fiddes, Pharmacotherapy. 17Herrera CR, Lewin A, Fiddes R, et al. Long-acting diltiazem CD is safe and effective in a hypertensive Mexican-American population. Pharmacotherapy 1997; 17: 1254-9

Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the Chrono trial. L M Prisant, M Weber, H R Black, J Natl Med Assoc. 97Prisant LM, Weber M, Black HR. Chronotherapeutic oral drug absorption system verapamil is effective in reducing morning blood pressure in African Americans: a post hoc analysis of the Chrono trial. J Natl Med Assoc 2005; 97: 377-83

One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. H R Black, W J Elliott, M A Weber, Hypertension. 38Black HR, Elliott WJ, Weber MA, et al. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension 2001; 38: 1118-23

Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. N T Fuenmayor, B M Faggin, L X Cubeddu, Drugs. 44SupplFuenmayor NT, Faggin BM, Cubeddu LX. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients. Drugs 1992; 44 Suppl. 1: 1-11

Comparative efficacy, safety, and kinetics of immediate-and slow-release verapamil in Hispanic patients with essential hypertension. N T Fuenmayor, B M Faggin, L X Cubeddu, J Cardiovasc Pharmacol. 13SupplFuenmayor NT, Faggin BM, Cubeddu LX. Comparative efficacy, safety, and kinetics of immediate-and slow-release verapamil in Hispanic patients with essential hypertension. J Cardiovasc Pharmacol 1989; 13 Suppl. 4: S53-6

Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics. V C Dias, B Tendler, S Oparil, Am J Ther. 6Dias VC, Tendler B, Oparil S, et al. Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hyper- tension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics. Am J Ther 1999; 6: 19-24

a2-agonist versus a1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin monotherapies. S I Harris, C Alvarez, Am J Ther. 4Harris SI, Alvarez C. a2-agonist versus a1-antagonist in mild-to-moderate hypertension: comparison of transdermal clonidine and terazosin mono- therapies. Am J Ther 1997; 4: 9-15

Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. M R Weir, S G Chrysant, D A Mccarron, Hypertension. 31Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme in- hibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hy- pertension 1998; 31: 1088-96

Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. B M Everett, R J Glynn, E Danielson, Clin Ther. 30Everett BM, Glynn RJ, Danielson E, et al. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial. Clin Ther 2008; 30: 661-72

The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. R A Phillips, R A Kloner, Grimm Jr, R H , J Clin Hypertens (Greenwich ). 5Phillips RA, Kloner RA, Grimm Jr RH, et al. The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension. J Clin Hypertens (Greenwich ) 2003; 5: 17-23

Moderate versus intensive treatment of hypertension using amlodipine valsartan and with the addition of hydrochlorothiazide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial ethnic subgroups. E O Ofili, S Oparil, T Giles, J Am Soc Hypertens. 5Ofili EO, Oparil S, Giles T, et al. Moderate versus intensive treatment of hyper- tension using amlodipine valsartan and with the addition of hydrochlorothia- zide for patients uncontrolled on angiotensin receptor blocker monotherapy: results in racial ethnic subgroups. J Am Soc Hypertens 2011; 5: 249-58

Efficacy and safety of fixed combinations of irbesartan hydrochlorothiazide in hypertensive women: the INCLUSIVE trial. E O Ofili, G Cable, J M Neutel, J Womens Health (Larchmt ). 17Ofili EO, Cable G, Neutel JM, et al. Efficacy and safety of fixed combinations of irbesartan hydrochlorothiazide in hypertensive women: the INCLUSIVE trial. J Womens Health (Larchmt ) 2008; 17: 931-8

Ethnic differences in response to combination aliskiren HCTZ vs ramipril monotherapy in obese patients with stage 2 hypertension. A Whaley-Connell, D Purkayastha, Z Ricks, abstract PO-67Whaley-Connell A, Purkayastha D, Ricks Z, et al. Ethnic differences in response to combination aliskiren HCTZ vs ramipril monotherapy in obese patients with stage 2 hypertension [abstract PO-67].

. J Clin Hypertens. 12SupplJ Clin Hypertens 2010; 12 Suppl. 1: A46-7

Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ): a subgroup analysis by ethnicity and BMI. T Littlejohn, S Oparil, M Melino, Diabetes. 592134abstract 2134-PO. SupplLittlejohn T, Oparil S, Melino M, et al. Efficacy and safety of combination olmesartan medoxomil (OM)+amlodipine besylate (AML)+hydrochlorothiazide (HCTZ): a subgroup analysis by ethnicity and BMI [abstract 2134-PO]. Diabetes 2010; 59 Suppl. 1: 2134

Aliskiren alone or in combination with hydrochlorothiazide lowers BP effectively in Hispanic Latino patients with systolic BP 160-<180 mm Hg (AQUIRE study). H R Black, F A Palacios, J L Arango, abstract PO-16Black HR, Palacios FA, Arango JL, et al. Aliskiren alone or in combination with hydrochlorothiazide lowers BP effectively in Hispanic Latino patients with systolic BP 160-<180 mm Hg (AQUIRE study) [abstract PO-16].

. J Clin Hypertens. 12124SupplJ Clin Hypertens 2010; 12 Suppl 1: A24

Combination direct renin inhibitor calcium channel blocker with or without diuretic effectively lowers blood pressure (BP) in Hispanic patients with stage 2 hypertension: a subgroup analysis of the aliksiren+amlodipine-HCTZ in minority patients with stage 2 hypertension (ASCENT) study [abstract P174. K Ferdinand, R Weitzman, D Purkayastha, Hypertension. 58Ferdinand K, Weitzman R, Purkayastha D, et al. Combination direct renin in- hibitor calcium channel blocker with or without diuretic effectively lowers blood pressure (BP) in Hispanic patients with stage 2 hypertension: a subgroup anal- ysis of the aliksiren+amlodipine-HCTZ in minority patients with stage 2 hy- pertension (ASCENT) study [abstract P174]. Hypertension 2011; 58: e78-9

Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). G Mancia, De Backer, G Dominiczak, A , Eur Heart J. 28Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the man- agement of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536

Renin-Angiotensin-aldosterone system in diabetes and hypertension. W A Hsueh, K Wyne, J Clin Hypertens (Greenwich ). 13Hsueh WA, Wyne K. Renin-Angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich ) 2011; 13: 224-37

Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. K S Hershon, Endocr Pract. 17Hershon KS. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease. Endocr Pract 2011; 17: 430-40

Diabetic microvascular complications: possible targets for improved macrovascular outcomes. J A D&apos;elia, G Bayliss, B Roshan, Int J Nephrol Renovasc Dis. 4D'Elia JA, Bayliss G, Roshan B, et al. Diabetic microvascular complications: possible targets for improved macrovascular outcomes. Int J Nephrol Ren- ovasc Dis 2011; 4: 1-15

Central pressure and biomarker responses to renin inhibition with hydrochlorothiazide and ramipril in obese hypertensive: the ATTAIN study. A Whaley-Connell, D Purkayastha, A Yadao, Cardiorenal Med. 1Whaley-Connell A, Purkayastha D, Yadao A, et al. Central pressure and bio- marker responses to renin inhibition with hydrochlorothiazide and ramipril in obese hypertensive: the ATTAIN study. Cardiorenal Med 2011; 1: 53-66

Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. S Oparil, M Melino, J Lee, Clin Ther. 327Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hyper- tension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32 (7): 1252-69

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. Y Uresin, A A Taylor, C Kilo, J Renin Angiotensin Aldosterone Syst. 8Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-8

Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: the ACQUIRE randomized double-blind study. H R Black, A Kribben, P F Aguirre, J Clin Hypertens (Greenwich ). 12Black HR, Kribben A, Aguirre PF, et al. Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hyper- tension: the ACQUIRE randomized double-blind study. J Clin Hypertens (Greenwich ) 2010; 12: 917-26

Efficacy and safety of aliskirenbased dual and triple combination therapies in US minority patients with stage 2 hypertension. K C Ferdinand, R Weitzman, M Israel, J Am Soc Hypertens. 5Ferdinand KC, Weitzman R, Israel M, et al. Efficacy and safety of aliskiren- based dual and triple combination therapies in US minority patients with stage 2 hypertension. J Am Soc Hypertens 2011; 5: 102-13

Director of Outpatient Clinics, The George Washington University Medical Faculty Associates, Division of Renal Diseases and Hypertension, 2150 Pennsylvania Avenue NW, Suite 3-425. J Nicolas, Guzman, Md, Washington, DC 20037, USA. E-mailnguzman@mfa.gwu.eduCorrespondence: Nicolas J Guzman, MD, Director of Outpatient Clinics, The George Washington University Medical Faculty Associates, Division of Renal Diseases and Hypertension, 2150 Pennsylvania Avenue NW, Suite 3-425, Washington, DC 20037, USA. E-mail: nguzman@mfa.gwu.edu